Trial site
McLaren Cancer Institute-Bloomfield
Bloomfield, Michigan 48302, United StatesNot linked to an institution yet
- 8running trials
- 2closed trials
The trials here
What the 11 trials at this site are about, from their registry records.
- Phase
- Phase 37 trials
- Phase 24 trials
- Status
- Active, not recruiting8 trials
- Completed2 trials
- Suspended1 trial
- Lead sponsor
- National Cancer Institute (NCI)4 trials
- ECOG-ACRIN Cancer Research Group2 trials
- SWOG Cancer Research Network2 trials
- Alliance for Clinical Trials in Oncology1 trial
- NRG Oncology1 trial
- and 1 more
Running trials
Active, not recruiting
A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery
NCT03809000· Phase 2· RTOG Foundation, Inc.· Source
Active, not recruiting
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
NCT03233711· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
NCT03419234· Phase 2· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
NCT02997228· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
NCT02912559· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Breast Cancer WEight Loss Study (BWEL Study)
NCT02750826· Phase 3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
NCT02445391· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT02488967· Phase 3· NRG Oncology· Source
Report an error